🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Karuna Therapeutics, Inc., a Bristol Myers Squibb company clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK, India and China registers with Karuna Therapeutics, Inc., a Bristol Myers Squibb company as lead sponsor. Synced 26 Sep 2026
8Current trials
8Recruiting now
2Drugs in these trials
4Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 8 current clinical trials in our USA, UK, India and China registers. 8 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are KarXT and Ondansetron. The most-studied condition is Psychosis Associated With Alzheimer's Disease.

ClinicalTrials.gov trials by status

  • Recruiting8100%

Trials by phase

  • Phase 3675%
  • Phase 1113%
  • Phase 4113%
01

Clinical trials sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787 · ClinicalTrials.gov ↗ · Alzheimer Disease
Drug: KarXT
Phase 3 Recruiting 2024-09 USA, India, China
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363 · ClinicalTrials.gov ↗ · Psychosis Associated With Alzheimer's Disease
Drug: KarXT
Phase 3 Recruiting 2022-08 UK, USA, India
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949 · ClinicalTrials.gov ↗ · Psychosis Associated With Alzheimer's Disease
Drug: KarXT
Phase 3 Recruiting 2023-07 UK, USA, India, China
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
NCT07204418 · ClinicalTrials.gov ↗ · Healthy Volunteers
Phase 1 Recruiting 2025-10 USA
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224 · ClinicalTrials.gov ↗ · Psychosis Associated With Alzheimer's Disease
Drug: KarXT
Phase 3 Recruiting 2023-08 UK, USA, China
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263 · ClinicalTrials.gov ↗ · Schizophrenia
Drug: KarXT
Phase 3 Recruiting 2026-08 UK, USA
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
NCT07681076 · ClinicalTrials.gov ↗ · Healthy Volunteers
Phase 4 Recruiting 2026-09 USA
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
NCT07424404 · ClinicalTrials.gov ↗ · Schizophrenia, Autism-Related Irritability
Drug: KarXT
Phase 3 Recruiting 2026-04 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Karuna Therapeutics, Inc., a Bristol Myers Squibb company trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Karuna Therapeutics, Inc., a Bristol Myers Squibb company trials

5 conditions
Psychosis Associated With Alzheimer's Disease3Schizophrenia2Healthy Volunteers2Alzheimer Disease1Autism-Related Irritability1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA88
Clinical trials in UK44
Clinical trials in India33
Clinical trials in China33

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Psychosis Associated With Alzheimer's Disease

SponsorTrials
MapLight Therapeutics2

Sponsors with the most current trials registered for this condition.

06

Questions about Karuna Therapeutics, Inc., a Bristol Myers Squibb company trials

How many clinical trials does Karuna Therapeutics, Inc., a Bristol Myers Squibb company sponsor?

Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 8 current trials on ClinicalTrials.gov in our USA, UK, India and China registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Karuna Therapeutics, Inc., a Bristol Myers Squibb company trials recruiting?

Yes. 8 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Karuna Therapeutics, Inc., a Bristol Myers Squibb company testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are KarXT (7) and Ondansetron (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.